FY2027 EPS Estimates for Journey Medical Reduced by B. Riley

Journey Medical Co. (NASDAQ:DERM) – Equities research analysts at B. Riley decreased their FY2027 earnings per share estimates for Journey Medical in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst K. Patel now expects that the company will post earnings of $0.31 per share for the year, down from their prior estimate of $0.39. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.30. The business had revenue of $14.30 million during the quarter, compared to analysts’ expectations of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Separately, Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a report on Thursday, March 27th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Journey Medical currently has an average rating of “Buy” and an average price target of $9.67.

Journey Medical Stock Up 1.2 %

NASDAQ:DERM opened at $5.97 on Monday. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a 1-year low of $3.20 and a 1-year high of $6.89. The company has a 50-day moving average of $5.18 and a 200 day moving average of $5.18. The firm has a market cap of $124.71 million, a PE ratio of -6.35 and a beta of 0.97.

Insiders Place Their Bets

In other news, CEO Claude Maraoui sold 49,271 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total value of $246,847.71. Following the completion of the sale, the chief executive officer now owns 2,003,147 shares of the company’s stock, valued at $10,035,766.47. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 105,831 shares of company stock valued at $536,622. 13.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Journey Medical by 13.5% during the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after acquiring an additional 12,882 shares during the last quarter. PVG Asset Management Corp boosted its stake in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after purchasing an additional 9,005 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in Journey Medical in the 3rd quarter worth approximately $66,000. Citadel Advisors LLC purchased a new stake in Journey Medical during the 4th quarter worth approximately $174,000. Finally, Cetera Investment Advisers increased its stake in Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares in the last quarter. 7.25% of the stock is owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.